Orchid Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE191A01027
  • NSEID: ORCHPHARMA
  • BSEID: 524372
INR
959.65
9.2 (0.97%)
BSENSE

Nov 20

BSE+NSE Vol: 70.15 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Morepen Labs.
Innova Captab
Bliss GVS Pharma
IOL Chemicals
Sanofi India
Orchid Pharma
Senores Pharma.
SPARC
Evonile Pharma
FDC
Supriya Lifesci.
Why is Orchid Pharma Ltd ?
1
Poor long term growth as Net Sales has grown by an annual rate of 22.51% and Operating profit at 19.31% over the last 5 years
2
Positive results in Sep 26
  • PBT LESS OI(Q) At Rs 9.08 cr has Grown at 1383.4% (vs previous 4Q average)
  • NET SALES(9M) Higher at Rs 1,013.77 cr
  • PAT(Q) Highest at Rs 28.59 cr.
3
Stock is technically in a Mildly Bullish range
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band and KST
4
With ROCE of 1.3, it has a Very Expensive valuation with a 2.9 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 10.44%, its profits have risen by 43.6% ; the PEG ratio of the company is 5.1
5
Majority shareholders : Promoters
6
Market Beating Performance
  • The stock has generated a return of 10.44% in the last 1 year, much higher than market (BSE500) returns of 0.37%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Orchid Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Orchid Pharma for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Orchid Pharma
10.44%
0.23
45.89%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
22.51%
EBIT Growth (5y)
19.31%
EBIT to Interest (avg)
2.47
Debt to EBITDA (avg)
5.13
Net Debt to Equity (avg)
0.30
Sales to Capital Employed (avg)
0.61
Tax Ratio
0.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.37%
ROCE (avg)
2.10%
ROE (avg)
5.01%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
110
Industry P/E
40
Price to Book Value
3.53
EV to EBIT
226.51
EV to EBITDA
89.41
EV to Capital Employed
2.94
EV to Sales
5.12
PEG Ratio
5.09
Dividend Yield
NA
ROCE (Latest)
1.30%
ROE (Latest)
3.21%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

22What is working for the Company
PBT LESS OI(Q)

At Rs 9.08 cr has Grown at 1383.4% (vs previous 4Q average

NET SALES(9M)

Higher at Rs 1,013.77 cr

PAT(Q)

Highest at Rs 28.59 cr.

EPS(Q)

Highest at Rs 4.77

-5What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 56.27 cr

NON-OPERATING INCOME(Q)

is 66.17 % of Profit Before Tax (PBT

Loading Valuation Snapshot...
Here's what is working for Orchid Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 9.08 cr has Grown at 1383.4% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs -0.71 Cr
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 28.59 cr has Grown at 399.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 5.72 Cr
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Nine Monthly
At Rs 1,013.77 cr has Grown at 26.86%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 28.59 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 4.77
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Net Sales - Nine Monthly
Higher at Rs 1,013.77 cr
than preceding 12 month period ended Sep 2026 of Rs 1,006.40 cr
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (Rs Cr)

Here's what is not working for Orchid Pharma
Non Operating Income - Quarterly
is 66.17 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT

Cash and Cash Equivalents - Half Yearly
Lowest at Rs 56.27 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Non Operating Income - Quarterly
Highest at Rs 17.76 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income